Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People's Republic of China and the United States. The company develops TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric and gastroesophageal cancer; TST808, a humanized antibody neutralizing APRIL targeting B/plasma cell; TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate for IgA kidney diseases. It also develops TST106, a humanized bispecific antibody-based drug conjugate targeting CLDN18.2 and an undisclosed tumor antigen; TST198, a Claudin18.2 targeting solid tumors; TST786 is a trispecific antibody targeting PD1, VEGF, and GREMLIN-1; TST013 is an ADC targeting LIV-1 target antigen for breast cancer and other tumor types; TST003, a regulatory protein expressed by stromal cells and tumor cells, including colon, prostate, gastric, lung, esophageal, pancreatic, and breast cancers; TST008, a bi-functional antibody for MASP-2 and BAFF for autoimmune diseases; and TST105, a bispecific ADC candidate targeting FGFR2b and an undisclosed tumor. It has research collaboration with Alebund Pharmaceuticals, Dana-Farber Cancer Institute, and John Hopkins University. The company was formerly known as MabSpace International Limited and changed its name to Transcenta Holding Limited in June 2019. The company was incorporated in 2010 and is headquartered in Suzhou, the People's Republic of China.
